Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer

Matthew D. Taylor, Philip W. Smith, William K. Brix, Mark R. Wick, Nicholas Theodosakis, Brian R. Swenson, Benjamin D. Kozower, Christine L. Lau, David R. Jones

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission tomography (FDG-PET). Both FDG-PET maximal standardized uptake values and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in non-small cell lung cancer (NSCLC). However, there are limited data correlating FDG-PET with tumor markers. The purpose of this study was to determine the correlation of tumor marker expression with FDG-PET maximal standardized uptake values in NSCLC. Methods: FDG-PET maximal standardized uptake values were calculated in patients with NSCLC (n = 149). No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose transporter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based on histologic characteristics and regional nodal status was performed. Results: FDG-PET correlated with T classification (P < .0001), N stage (P = .002), and greatest tumor dimension (P < .0001). In addition, increasing maximal standardized uptake values correlated with increased expression of glucose transporter 1 (P < .0001) and p53 (P = .04) in adenocarcinoma. Epidermal growth factor receptor expression correlated with maximal standardized uptake values without predilection for histologic subtype (P = .004). Conclusion: FDG-PET maximal standardized uptake values correlate with an increased expression of glucose transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to correlate FDG-PET with tumor biology will need to consider the effect of different tumor histologic types.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume137
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Tumor Biomarkers
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Facilitative Glucose Transport Proteins
Epidermal Growth Factor Receptor
Neoplasms
Squamous Cell Neoplasms
Cyclin D1
Chemoradiotherapy
Vascular Endothelial Growth Factor A
Adenocarcinoma
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Taylor, Matthew D. ; Smith, Philip W. ; Brix, William K. ; Wick, Mark R. ; Theodosakis, Nicholas ; Swenson, Brian R. ; Kozower, Benjamin D. ; Lau, Christine L. ; Jones, David R. / Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. In: Journal of Thoracic and Cardiovascular Surgery. 2009 ; Vol. 137, No. 1. pp. 43-48.
@article{1ac9145125724a259f5d91e41152a79e,
title = "Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer",
abstract = "Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission tomography (FDG-PET). Both FDG-PET maximal standardized uptake values and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in non-small cell lung cancer (NSCLC). However, there are limited data correlating FDG-PET with tumor markers. The purpose of this study was to determine the correlation of tumor marker expression with FDG-PET maximal standardized uptake values in NSCLC. Methods: FDG-PET maximal standardized uptake values were calculated in patients with NSCLC (n = 149). No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose transporter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based on histologic characteristics and regional nodal status was performed. Results: FDG-PET correlated with T classification (P < .0001), N stage (P = .002), and greatest tumor dimension (P < .0001). In addition, increasing maximal standardized uptake values correlated with increased expression of glucose transporter 1 (P < .0001) and p53 (P = .04) in adenocarcinoma. Epidermal growth factor receptor expression correlated with maximal standardized uptake values without predilection for histologic subtype (P = .004). Conclusion: FDG-PET maximal standardized uptake values correlate with an increased expression of glucose transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to correlate FDG-PET with tumor biology will need to consider the effect of different tumor histologic types.",
author = "Taylor, {Matthew D.} and Smith, {Philip W.} and Brix, {William K.} and Wick, {Mark R.} and Nicholas Theodosakis and Swenson, {Brian R.} and Kozower, {Benjamin D.} and Lau, {Christine L.} and Jones, {David R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.jtcvs.2008.10.014",
language = "English (US)",
volume = "137",
pages = "43--48",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. / Taylor, Matthew D.; Smith, Philip W.; Brix, William K.; Wick, Mark R.; Theodosakis, Nicholas; Swenson, Brian R.; Kozower, Benjamin D.; Lau, Christine L.; Jones, David R.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 137, No. 1, 01.01.2009, p. 43-48.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer

AU - Taylor, Matthew D.

AU - Smith, Philip W.

AU - Brix, William K.

AU - Wick, Mark R.

AU - Theodosakis, Nicholas

AU - Swenson, Brian R.

AU - Kozower, Benjamin D.

AU - Lau, Christine L.

AU - Jones, David R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission tomography (FDG-PET). Both FDG-PET maximal standardized uptake values and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in non-small cell lung cancer (NSCLC). However, there are limited data correlating FDG-PET with tumor markers. The purpose of this study was to determine the correlation of tumor marker expression with FDG-PET maximal standardized uptake values in NSCLC. Methods: FDG-PET maximal standardized uptake values were calculated in patients with NSCLC (n = 149). No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose transporter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based on histologic characteristics and regional nodal status was performed. Results: FDG-PET correlated with T classification (P < .0001), N stage (P = .002), and greatest tumor dimension (P < .0001). In addition, increasing maximal standardized uptake values correlated with increased expression of glucose transporter 1 (P < .0001) and p53 (P = .04) in adenocarcinoma. Epidermal growth factor receptor expression correlated with maximal standardized uptake values without predilection for histologic subtype (P = .004). Conclusion: FDG-PET maximal standardized uptake values correlate with an increased expression of glucose transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to correlate FDG-PET with tumor biology will need to consider the effect of different tumor histologic types.

AB - Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission tomography (FDG-PET). Both FDG-PET maximal standardized uptake values and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in non-small cell lung cancer (NSCLC). However, there are limited data correlating FDG-PET with tumor markers. The purpose of this study was to determine the correlation of tumor marker expression with FDG-PET maximal standardized uptake values in NSCLC. Methods: FDG-PET maximal standardized uptake values were calculated in patients with NSCLC (n = 149). No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose transporter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based on histologic characteristics and regional nodal status was performed. Results: FDG-PET correlated with T classification (P < .0001), N stage (P = .002), and greatest tumor dimension (P < .0001). In addition, increasing maximal standardized uptake values correlated with increased expression of glucose transporter 1 (P < .0001) and p53 (P = .04) in adenocarcinoma. Epidermal growth factor receptor expression correlated with maximal standardized uptake values without predilection for histologic subtype (P = .004). Conclusion: FDG-PET maximal standardized uptake values correlate with an increased expression of glucose transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to correlate FDG-PET with tumor biology will need to consider the effect of different tumor histologic types.

UR - http://www.scopus.com/inward/record.url?scp=58249083794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249083794&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2008.10.014

DO - 10.1016/j.jtcvs.2008.10.014

M3 - Article

C2 - 19154901

AN - SCOPUS:58249083794

VL - 137

SP - 43

EP - 48

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -